cas 1332524-01-2|| where to buy methyl 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoate

Product Name:methyl 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoate

IUPAC Name:methyl 2-{[3-fluoro-4-(methylcarbamoyl)phenyl]amino}-2-methylpropanoate

Packing Unit	Available Stock	Price($)
CM132205-1g	3-4 Weeks	ƎƦư
CM132205-5g	3-4 Weeks	ȬƎȁ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1332524-01-2 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1332524-01-2; Molecular Formula:C13H17FN2O3; Melting Point:-; Smiles Code:CC(C)(NC1=CC=C(C(NC)=O)C(F)=C1)C(OC)=O; Density:

: Catalog Number:CM132205; Molecular Weight:268.29; Boiling Point:; MDL No:MFCD22581652; Storage:

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Enzalutamide; Aug. 23, 2023, FDA grants priority review for XTANDI(enzalutamide) in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
XTANDI (enzalutamide) is an androgen receptor signaling inhibitor. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.XTANDI is currently approved for one or more of these indications in more than 100 countries, including in the U.S., European Union and Japan. Over one million patients have been treated with XTANDI globally.